ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Nevertheless, BCR/ABL1 inhibition with imatinib (Gleevec), a tyrosine kinase inhibitor, resulting in ceasing disease progression, was the first success of cancer targeted therapy, changing CML from a fatal disorder into a chronic disease [64].